Retrospective Study
Copyright ©The Author(s) 2019.
World J Gastrointest Oncol. Nov 15, 2019; 11(11): 1043-1053
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1043
Table 1 Patient characteristics
VariableTotal (n = 181)Benign (n = 94)Malignant (n = 87)P valuea
Age, yr61 (29-79)61 (41-79)60 (29-77)0.672
Sex (%)0.136
Male108 (59.7)61 (64.9)47 (54.0)
Female73 (40.3)33 (35.1)40 (46.0)
Symptoms (%)0.008
Yes111 (61.3)49 (52.1)62 (71.3)
No70 (38.7)45 (47.9)25 (28.7)
Weight loss (%)0.322
Yes42 (23.2)19 (20.2)23 (26.4)
No139 (76.8)75 (79.8)64 (73.6)
Jaundice (%)< 0.001
Yes17 (9.4)2 (2.1)15 (17.2)
No164 (90.6)92 (97.9)72 (82.8)
Location (%)0.185
Head105 (58.0)58 (61.7)47 (54.0)
Body and tail71 (39.2)32 (34.0)39 (44.8)
Diffuse/multifocal5 (2.8)4 (4.3)1 (1.2)
Type of lesion (%)< 0.001
MD96 (53.0)24 (25.6)72 (82.8)
BD68 (37.6)60 (63.8)8 (9.2)
Mixed17 (9.4)10 (10.6)7 (8.0)
Type of surgery (%)0.316
PD/PPPD102 (56.4)58 (61.7)44 (50.6)
DP66 (36.4)30 (31.9)36 (41.4)
TP12 (6.6)5 (5.3)7 (8.0)
Enucleation1 (0.6)1 (1.1)0 (0.0)
Mural nodule/solid component (%)< 0.001
Yes98 (54.1)36 (38.3)62 (71.3)
No83 (45.9)58 (61.7)25 (28.7)
Size, mm10 (2-60)9 (3-21)13 (3-60)< 0.001
MPD diameter, mm5 (1-29)3 (1-20)7 (2-29)< 0.001
Cyst size of BD-IPMN, mm25 (8-90)24 (10-90)25 (8-46)0.702
Serum CA19-9, U/mL25.3 (0.6-2125.0)13.6 (0.6-313.0)77.9 (0.6-2125.0)< 0.001
Serum CEA, ng/mL2.8 (0.5-79.2)2.6 (0.5-15.0)3.4 (0.8-79.2)0.015
Serum amylase, U/L65 (7.3-804.0)72 (7.3-804.0)60.0 (21.0-367.0)0.278
Table 2 Comparison of the four models and the International Consensus Guidelines 2017
SensitivitySpecificityPPVNPVAccuracy
PSC model0.8390.7660.7680.8370.801
JPS model0.6550.7020.6710.6880.680
JHH model0.8280.6170.6670.7950.718
JPN-KOR model0.3750.8170.2140.9070.765
ICG 20170.9080.4470.6030.8400.669
Our nomogram0.8390.8400.8300.8490.840